Survodutide is supplied as a dual glp-1/glucagon receptor agonist peptide for qualified laboratory research. It is intended for a modified oxyntomodulin analogue used in laboratory studies of GLP-1 and glucagon receptor signalling, receptor pharmacology, peptide characterisation and analytical method development. Available specifications: 5 mg, 10 mg, 15 mg; 10 vials per box. For laboratory research use only. Not for human consumption, clinical use, diagnosis, treatment, compounding or veterinary use.